NCT06917079 2026-03-18BBO-11818 in Adult Subjects With KRAS Mutant CancerTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Phase 1 Recruiting387 enrolled
NCT07223047 2026-03-17A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesBristol-Myers SquibbPhase 1/2 Recruiting252 enrolled
NCT06179160 2026-03-16A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationIncyte CorporationPhase 1 Recruiting710 enrolled
NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT06704724 2026-03-13A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.PfizerPhase 1 Active not recruiting30 enrolled
NCT06835569 2026-03-09A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS MutationsAlterome Therapeutics, Inc.Phase 1 Recruiting188 enrolled
NCT07020221 2026-03-09A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsVerastem, Inc.Phase 1/2 Recruiting295 enrolled
NCT06447662 2026-02-25A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.PfizerPhase 1 Recruiting330 enrolled